Channel Pharma (PTHS) - Koefisien utang jangka dawa marang modal

Channel Therapeutics utilizes algorithms and automation for the synthesis of neuropreparations, although trials remain the responsibility of physicians. Dependence on external capital and the risk of FDA rejections create uncertainty. Diversification of molecules for ion channels mitigates regulatory threats. The long-term financial dependence ratio, as formed by GURU.Markets quotes, shows that the 0.00 indicator expresses the state of the long-term debt-to-equity metric.

The long-term reliability of the issuer is determined by the balance between external liabilities and internal reserves. This indicator measures the proportion of loans with a maturity of over one year relative to equity, assessing the degree of financial leverage. By analyzing long-term debt-to-equity, an investor can see the company's dependence on long-term borrowing. For Channel Therapeutics (PTHS), such a structure is optimal. Stable operating cash flows fully cover obligations, confirming the resilience of the business model.